SCHEMBL6171372

SCHEMBL6171372

CCOC(=O)C(C)C(C(C)=O)C(=O)OCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
LMNA P02545 2/20 0.44
HSD17B10 Q99714 1/20 0.44
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HPGD P15428 2/20 0.38
MAPT P10636 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
GAA P10253 2/20 0.37
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
TRPA1 O75762 1/20 0.34
GLO1 Q04760 1/20 0.34
PKM P14618 2/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11257898 0.93 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2
SCHEMBL9617476 0.91 ALDH1A1 (0.44) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2
SCHEMBL5075813 0.88 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2
SCHEMBL11648171 0.87 TP53 (0.41) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2
SCHEMBL4944171 0.85 ALDH1A1 (0.52) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2
SCHEMBL19703069 0.85 SMN1; SMN2 (0.38) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2
SCHEMBL1919905 0.84 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2
SCHEMBL10253096 0.84 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2
SCHEMBL14946230 0.82 ALDH1A1 (0.44) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2
SCHEMBL4148198 0.80 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0022440-A1 Process for preparing Michael addition products and for converting them to ibuprofen, an anti-inflammatory compound THE UPJOHN COMPANY (US) 1981-01-21 EP claimed
US-4194053-A Process for preparing esters of α-acetyl-α'-methylsuccinic acid and esters of α-methyl-α'-acetyl-α'-(5-methyl-3-oxohexyl)succinic acid THE UPJOHN COMPANY (US) 1980-03-18 US claimed
US-6953789-B2 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-10-11 US disclosed
US-20040157894-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
US-6699881-B2 MATRIX METALLOPROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-02 US disclosed
US-20030078253-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2003-04-24 US disclosed
US-6420415-B1 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-16 US disclosed
EP-1132379-A1 NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed
US-4338459-A FROM 2-HALOPROPIONATE ESTER AND ACETOACETIC ACID ESTER THE UPJOHN COMPANY (US) 1982-07-06 US disclosed
EP-0022440-A1 Process for preparing Michael addition products and for converting them to ibuprofen, an anti-inflammatory compound THE UPJOHN COMPANY (US) 1981-01-21 EP disclosed
US-4194053-A Process for preparing esters of α-acetyl-α'-methylsuccinic acid and esters of α-methyl-α'-acetyl-α'-(5-methyl-3-oxohexyl)succinic acid THE UPJOHN COMPANY (US) 1980-03-18 US disclosed
US-4008270-A Process for preparing 2-(substituted phenyl)propionic acids THE UPJOHN COMPANY (US) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078253-A1 Thiol compounds, their production and use TST, QSOX1, SULT1E1 ALDH1A1 905/4885LMNA 4373/4885HSD17B10 520/4885
US-20040157894-A1 Thiol compounds, their production and use TST, SULT1E1, QSOX1 ALDH1A1 877/4885LMNA 4464/4885HSD17B10 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.